PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12768320-1	2003	PURPOSE: Based on prior studies demonstrating the effect of 13- cis-retinoic acid and interferon alpha (CRA/IFN) in decreasing the expression of the antiapoptotic protein bcl-2, our prior clinical study of CRA/IFN with paclitaxel (TAX) administered every 3 weeks, and data demonstrating increased activity of weekly TAX against prostate cancer, we designed a phase I study of weekly TAX in combination with CRA/IFN in patients with prostate cancer and other advanced malignancies.	Isotretinoin	60-81	BCL2 apoptosis regulator	Homo sapiens	171-176	
20084480-0	2010	Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells.	Isotretinoin	28-48	BCL2 apoptosis regulator	Homo sapiens	126-131	
25304678-3	2014	The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer.	Isotretinoin	134-154	BCL2 apoptosis regulator	Homo sapiens	116-121	
24858462-0	2014	Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).	Isotretinoin	22-42	BCL2 apoptosis regulator	Homo sapiens	57-62	
24858462-3	2014	We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC.	Isotretinoin	70-90	BCL2 apoptosis regulator	Homo sapiens	59-64	
21159604-0	2010	Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.	Isotretinoin	68-88	BCL2 apoptosis regulator	Homo sapiens	122-127	
21159604-9	2010	Thus, combining 13-cis-RA with cytotoxic chemotherapy significantly reduced the cytotoxicity for neuroblastoma in vitro, mediated at least in part via the antiapoptotic Bcl-2 family of proteins.	Isotretinoin	16-25	BCL2 apoptosis regulator	Homo sapiens	169-174	
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Isotretinoin	65-85	BCL2 apoptosis regulator	Homo sapiens	54-59	
20178647-1	2010	BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).	Isotretinoin	87-90	BCL2 apoptosis regulator	Homo sapiens	54-59	
10621853-0	1999	bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study.	Isotretinoin	41-61	BCL2 apoptosis regulator	Homo sapiens	0-5	
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Isotretinoin	97-117	BCL2 apoptosis regulator	Homo sapiens	168-173	
10604265-4	1999	Of several agents recently shown to reduce prostate-specific antigen levels in phase II studies, 13-cis-retinoic acid and interferon-alpha can reduce the expression of bcl-2 and overcome bcl-2-mediated resistance to paclitaxel in resistant cell lines.	Isotretinoin	97-117	BCL2 apoptosis regulator	Homo sapiens	187-192	
10604265-5	1999	For these reasons, our current studies test the hypothesis that reducing the expression of bcl-2 with 13-cis-retinoic acid and interferon-alpha in combination with taxanes will improve clinical results.	Isotretinoin	102-122	BCL2 apoptosis regulator	Homo sapiens	91-96	
10638174-0	1999	The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin.	Isotretinoin	86-98	BCL2 apoptosis regulator	Homo sapiens	26-31	
10638174-1	1999	BACKGROUND: This study evaluates the role of bcl-2 protein, as well as, of apoptotic bodies in the topical treatment of oral leucoplakia with 13-cis-retinoic acid (isotretinoin).	Isotretinoin	142-162	BCL2 apoptosis regulator	Homo sapiens	45-50	
10621853-0	1999	bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study.	Isotretinoin	63-75	BCL2 apoptosis regulator	Homo sapiens	0-5